Patent
The invention relates to a new lutetium-177 therapeutic radiopharmaceutical as an inhibitor of prostate-specific membrane antigen (iPSMA), wherein 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″″-tetraacetic acid (DOTA) bonded to the heterocyclic molecule hydrazinonicotinamide (HYNIC), generates a rigid chemical structure that minimises the number of conformers and intramolecular hydrogen bonds, thereby producing a favourable spatial orientation of the active site (Lys(Nal)-NH—CO—NH-Glu) in the molecule, for biological recognition by the PSMA protein. The new 177Lu-DOTA-HYNIC-iPSMA radiopharmaceutical accumulates, with high affinity in vivo, in tumours that overexpress the PSMA protein, acting as a radiotherapeutic agent. The purpose of the invention is to provide a new specific radiopharmaceutical (molecular target radiopharmaceutical) for the treatment of tumours with PSMA overexpression.
1. A compound comprising a chelator-hydrazinonicotinamide (HYNIC)-prostate specific membrane antigen inhibitor (iPSMA), wherein the chelator is 1,4,7,10-tetraazacyclododecano-N,N′,N″,N″″-tetraacetic acid (DOTA), and wherein the compound has the structure
2. A radiopharmaceutical comprising the compound of claim 1 and a radionuclide.
3. The radiopharmaceutical of claim 2 having the formula 177 Lu-DOTA-HYNIC-iPSMA and comprising the structure
4. A radiopharmaceutical composition comprising the radiopharmaceutical of claim 3 .
5. The radiopharmaceutical composition of claim 4 comprising a 1 M sodium acetate buffer solution, pH 5.0.
6. The compound of claim 1 (DOTA-HYNIC-iPSMA) formulated as a lyophilized pharmaceutical form, for use in radiolabeling.
7. The compound of claim 6 , wherein the lyophilized pharmaceutical form contains 50 mg mannitol and 100 mg ascorbic acid.
8. A kit comprising
the compound of claim 1 (DOTA-HYNIC-iPSMA) formulated as a lyophilized pharmaceutical form containing 50 mg mannitol and 100 mg ascorbic acid, and
a 1 M sodium acetate buffer solution, pH 5.0, containing a radionuclide,
for use in radiolabeling.
9. A method of treating a patient with a tumor expressing prostate-specific membrane antigen (PSMA) protein, the method comprising administering to the patient a therapeutically effective amount of the radiopharmaceutical of claim 3 .
10. The method of claim 9 , wherein administration of the radiopharmaceutical to the patient is effective to decrease size and/or number of prostate cancer metastatic lesion sites.